Table 1.

KIR2DL2+/C1+/KIR3DL1+/Bw4+ influence patient EFS and OS depending on the treatment group (immunotherapy versus isotretinoin alone)

EFSOS
n (#Events)a2-yr % rate (95% CI)b5-yr % rate (95% CI)bPcn (#Events)a2-yr % rate (95% CI)b5-yr % rate (95% CI)bPc
KIR2DL2+/C1+ and KIR3DL1+/Bw4+Immunotherapy23 (11)83 (60–93)61 (38–77)0.0423 (7)96 (73–99)91 (69–98)0.01
Isotretinoin26 (19)27 (12–44)27 (12–44)26 (17)62 (40–77)34 (17–52)
KIR2DL2+/C1+ and not KIR3DL1+/Bw4+Immunotherapy35 (12)69 (50–81)66 (48–79)1.0035 (11)77 (59–88)69 (50–81)1.00
Isotretinoin35 (15)56 (38–71)56 (38–71)35 (13)86 (69–94)66 (47–80)
KIR3DL1+/Bw4+ and not KIR2DL2+/C1+Immunotherapy19 (9)58 (33–76)53 (29–72)1.0019 (7)84 (59–95)74 (48–88)0.67
Isotretinoin11 (6)41 (12–69)41 (12–69)11 (6)58 (23–82)35 (8–64)
not KIR2DL2+/C1+ and not KIR3DL1+/Bw4+Immunotherapy11 (7)45 (17–71)36 (11–63)1.0011 (6)73 (37–90)55 (23–78)0.39
Isotretinoin14 (6)71 (39–88)55 (26–77)14 (3)92 (57–99)92 (57–99)
  • NOTE: The combination of both KIR2DL2 with its ligand, together with KIR3DL1 with its ligand (top line in this table and corresponding to the genotype evaluated as solid lines in Fig. 3), has a statistically significant effect on both EFS and OS for patients in the immunotherapy group as compared with the isotretinoin-alone group. All other combinations of these genotypes (those KIR2DL2+/C1+, but not KIR3DL1+/Bw4+; those KIR3DL1+/Bw4+, but not KIR2DL2+/C1+; and those not KIR2DL2+/C1+ and also not KIR3DL1+/Bw4+) had no significant difference in EFS or OS for treatment group comparisons.

  • Abbreviation: yr, year.

  • an, number of individuals; “#Events,” number of individuals that had an event throughout the duration of the study [median follow-up among all patients: 6.7 years (0.2–13.2 years)].

  • b95% confidence interval (CI).

  • cP value adjusted using the Bonferonni method.